1stOncology™: Cancer Intelligence Service – Page 11888 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event

On November 18, 2020 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, reported that the company will participate in the EACR Liquid Biopsies Virtual Event, November 18-19, including a poster presentation and satellite symposia (Press release, Personalis, NOV 18, 2020, View Source [SID1234571358]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The company will showcase both their platforms, ImmunoID NeXT and NeXT Liquid Biopsy.

ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample, thus maximizing the biological information that can be generated from a precious tumor specimen.

NeXT Liquid Biopsy, a first-of-its-kind, high-performance exome-wide liquid biopsy assay, provides a unique ability to evaluate the cancer ecosystem and advance the development of next-generation therapies. While solid tumor biopsies remain the standard for the interrogation of the cancer genome, the advent of liquid biopsies has demonstrated there can be more to a cancer’s genotypic profile than that found in a single tissue biopsy. Therefore, the combination of NeXT Liquid Biopsy and ImmunoID NeXT delivers the most comprehensive view of a cancer’s mutational landscape by evaluating both the tissue and blood. NeXT Liquid Biopsy enables investigation into key applications such as spatial and temporal heterogeneity of the tumor, clonal evolution and tumor dynamics in response to therapies, and mechanisms of acquired resistance. In this presentation, we’ll highlight data demonstrating the genomic profiling and assay performance enabled by NeXT Liquid Biopsy through the evaluation of reference standards and patient samples.

Following are details for the Personalis presentations.

Scientific Poster Presentation

Poster Number

Title & Presenter

Dates

Sensitive detection and monitoring of genetic alterations in circulating cfDNA with an enhanced whole-exome approach
Presenter: Simo V. Zhang, PhD

NOV 18-19 | Online

Following are details of an industry-sponsored symposium which will be presented at the meeting.

Satellite Symposia

Title

Title & Presenter

Dates

Foundation Medicine Enters into Patent Licensing and Technology Agreement with TwinStrand Biosciences

On November 18, 2020 Foundation Medicine reported it has entered into a non-exclusive agreement to license two foundational patent families from TwinStrand Biosciences, a next-generation DNA sequencing technology company based in Seattle (Press release, Foundation Medicine, NOV 18, 2020, View Source [SID1234571357]).

The patented TwinStrand Duplex Sequencing technology is a biochemistry- and software-based platform that enables researchers and clinicians to detect faint signals of ultra-low frequency DNA mutations often obscured by technical noise.

"Advancing and improving patient care is our highest priority and we’re pleased to work with partners like TwinStrand who share this same goal," said Cindy Perettie, Foundation Medicine’s chief executive officer. "We look forward to expanding this agreement with TwinStrand to explore additional areas for future collaboration."

"We are delighted to partner with Foundation Medicine, a company that shares our patient-centric mission of applying innovative science to advance cancer care globally," said Jesse Salk, MD, PhD, TwinStrand’s chief executive officer. "We are excited to help power Foundation Medicine’s commitment to delivering the highest quality data and genomic insights to physicians and their patients."

Illumina to Webcast Upcoming Investor Conference Presentation

On November 18, 2020 Illumina, Inc. (NASDAQ:ILMN) reported that its executives will be speaking at the following investor conference and invited investors to participate via webcast (Press release, Illumina, NOV 18, 2020, View Source [SID1234571356]).

Piper Sandler Annual Healthcare Conference
Thursday, December 3, 2020 at 1:30pm Eastern Time

The live webcast can be accessed in the Investor Info section of Illumina’s web site under the "company" tab at www.illumina.com. A replay of the presentation will be posted on Illumina’s website as soon as possible after the event and will be available for at least 30 days following.

Agendia and Paige Announce Landmark Strategic Partnership to Revolutionize Treatment Planning in Breast Cancer

On November 18, 2020 Agendia, Inc., a world leader in precision oncology for breast cancer, and Paige, a global leader in AI-based digital diagnostics, reported a first of its kind strategic partnership that will redefine precision oncology (Press release, Agendia, NOV 18, 2020, View Source [SID1234571355]). The partnership will enable co-development of treatment planning tools that integrate the cloud-based Paige Platform with genomic information from Agendia’s proprietary MammaPrint and BluePrint diagnostic tests for patients with breast cancer. These new products will enable faster access to predictive and prognostic information along the entire continuum of care, from diagnosis and early intervention to metastatic treatment planning.

"Paige’s digital pathology platform is truly transformational for oncology and will catapult diagnostics forward as a whole. This partnership defines the democratization of treatment planning tools by accelerating access to these tests and the essential insights they provide for more patients globally," said Mark Straley, Chief Executive Officer of Agendia. "Our goal is to provide same-day turnaround in most cases, enable earlier intervention, preserve limited biopsy or surgical tissue specimens, and extend key benefits to physicians and their patients with access to testing in countries where tissue ‘send out’ is not allowed. Whether a patient is in Manhattan or Mumbai, the ability to get real-time and accurate results from Agendia’s MammaPrint and BluePrint tests will improve how we are treating breast cancer today."

The initial focus of the collaboration will be the development of digital tests for early treatment planning where genomic testing has played an essential role in determining recurrence risk and tumor biology as doctors and their patients make decisions about the path ahead. This can be especially important for patients with operable breast cancer. Beyond early intervention, AI-derived biomarkers will be used to augment genomic testing in the metastatic setting where a multitude of therapeutic options can add to the complexity of treatment planning.

"As the first company to receive FDA clearance, FDA breakthrough designation and two CE marks for digital and computational pathology products, Paige is delivering next-generation digital diagnostics that redefine how we approach cancer care," said Leo Grady, Ph.D., Chief Executive Officer of Paige. "By combining our unique capabilities with Agendia’s leadership in breast cancer, we believe this innovative partnership can achieve our shared goal of transforming clear and actionable information into precision treatment for better patient outcomes. It will be the first of many AI-based diagnostic tests to come."

NantKwest to Participate in the 32nd Annual Piper Sandler Healthcare Conference

On November 18, 2020 NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, reported its participation in the virtual 32nd Annual Piper Sandler Healthcare conference, which takes place December 1-3, 2020 (Press release, NantKwest, NOV 18, 2020, https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-participate-32nd-annual-piper-sandler-healthcare?field_nir_news_date_value[min]= [SID1234571353]). NantKwest Executive Chairman Patrick Soon-Shiong, M.D., and Chief Executive Officer Rich Adcock will participate in institutional investor meetings on Tuesday, December 1; meetings may be requested through Piper Sandler.

Additionally, a pre-recorded fireside chat with Dr. Soon-Shiong and Mr. Adcock will be accessible beginning November 23, 2020 on the Piper Sandler conference site and in the Investors section of NantKwest’s website, NantKwest.com. The recording will be available on the NantKwest website through December 31, 2020.